SNGXHealthcare · BiotechnologyThe 1 Wall Street analysts covering Soligenix, Inc. hold a median 12-month price target of $1.75 — +316.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Soligenix, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (93): Smaller than most of the companies we track.
Value (7): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SNGX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +316.7% from it.
Of the 10 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 July 2025 | Alliance Global Partners | Maintains | Buy | $10 → $6.00 |
| 4 Dec 2020 | B. Riley FBR | Initiates | Buy | — |
| 4 Dec 2020 | B. Riley Securities | Initiates | Buy | $4.00 |
| 28 July 2020 | Dawson James | Downgrade | Neutral | $3.00 → $2.00 |
| 31 Jan 2018 | H.C. Wainwright | Downgrade | Neutral | — |
| 31 Jan 2018 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 14 Aug 2017 | Maxim Group | Maintains | Buy | $4.00 → $5.00 |
| 17 July 2017 | H.C. Wainwright | Initiates | Buy | — |
| 17 July 2017 | HC Wainwright & Co. | Initiates | Buy | — |
| 7 Sept 2016 | Aegis Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SNGX appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 78% of US stocks
Cheaper than 65% of US stocks
Cheaper than 60% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 6% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Soligenix, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Soligenix, a biopharmaceutical company developing products to treat rare diseases with unmet medical need, announced its recent updates and financial results for the quarter ended June 30, 2026.
Why it matters — This announcement provides Soligenix watchers with an update on the company's operations and its financial position for the second quarter of 2026.
The 1 Wall Street analysts covering Soligenix, Inc. have a median 12-month price target of $1.75, with estimates ranging from $1.5 to $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Soligenix, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Soligenix, Inc. 28 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Soligenix, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +316.7% from the last close, and Ticker Nerd's factor model ranks Soligenix, Inc. 28 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Soligenix, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.5 to $2 over the next 12 months.
Soligenix, Inc. returned -87.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Soligenix Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
The most recent item we track (PRNewsWire, 7 Aug 2026): "Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results". Soligenix, a biopharmaceutical company developing products to treat rare diseases with unmet medical need, announced its recent updates and financial results for the quarter ended June 30, 2026.
Soligenix Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. It operates through two primary segments: Specialized BioTherapeutics, which targets therapies for conditions like cutaneous T-cell lymphoma with products such as HyBryte, and Public Health Solutions, addressing vaccines and treatments for biological threats and infectious diseases. The company advances innovative biopharmaceuticals, including synthetic hypericin formulations, emphasizing rapid response and strong safety profiles in clinical studies. Soligenix Inc. plays a vital role in the biopharma sector by addressing niche markets for orphan drugs and emergency countermeasures, contributing to advancements in rare disease management and public health preparedness. Founded in 1987 and headquartered in Princeton, New Jersey, it continues to prioritize late-stage development in these specialized areas.
CEO Dr. Christopher J. Schaber Ph.D. · 13 employees · United States · https://www.soligenix.com